Phase II/III study of MD-711 in patients with ILD-PH
Phase 2
- Conditions
- PH associated with ILD including CPFE
- Registration Number
- JPRN-jRCT2051210016
- Lead Sponsor
- Takahashi Kenta
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Patients who have diffuse parenchymal lung disease confirmed by chest high resolution computed tomography and any of the following diseases which are included in the Group 3 under the updated clinical classification of pulmonary hypertension:
Interstitial lung disease
Other pulmonary diseases with mixed restrictive and obstructive pattern
Exclusion Criteria
Patients who have any of the following diseases which are included in the Group 3 under the updated clinical classification of pulmonary hypertension:
Chronic obstructive pulmonary disease
Sleep-disordered breathing
Alveolar hypoventilation disorders
Chronic exposure to high altitude
Developmental lung diseases
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of change in PVRI, Amount of change in 6MWD
- Secondary Outcome Measures
Name Time Method